J
Jürgen Curschmann
Researcher at University of Bern
Publications - 7
Citations - 16851
Jürgen Curschmann is an academic researcher from University of Bern. The author has contributed to research in topics: Temozolomide & Cancer. The author has an hindex of 6, co-authored 6 publications receiving 14465 citations.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
TL;DR: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Journal ArticleDOI
Histologic characteristics and tumor spread of recurrent glottic carcinoma: analysis on whole-organ sections and comparison with tumor spread of primary glottic carcinomas.
TL;DR: The assessment of the precise tumor extent of recurrent glottic carcinomas is a challenge and the need for further research is to be determined.
Journal ArticleDOI
Radionecrosis or tumor recurrence after radiation of laryngeal and hypopharyngeal carcinomas
Peter Zbären,Marco Caversaccio,Harriet C. Thoeny,Michel Nuyens,Jürgen Curschmann,Edouard Stauffer +5 more
TL;DR: Chondroradionecrosis is a relatively rare treatment complication that may be present beneath an intact mucosa and missed by endoscopy and typical imaging findings suggestive of radionicrosis are often missing.
Journal ArticleDOI
Morbidity in 201 patients with small sized meningioma treated by microsurgery.
TL;DR: MS provides excellent efficacy and morbidity results in groups I and II meningiomas, especially in asymptomatic patients and might therefore be considered the first choice of treatment for these patients.
Journal ArticleDOI
Objective response to radiation therapy and long-term survival of patients with WHO grade II astrocytic gliomas with known LOH 1p/19q status.
Ali-Reza Fathi,Erik Vassella,Marlene Arnold,Jürgen Curschmann,Michael Reinert,Istvan Vajtai,Joachim Weis,Gianluca Deiana,Luigi Mariani +8 more
TL;DR: Approximately 50% of patients with astrocytic WHO grade II gliomas respond to RT despite the absence of LOH for 1p/19q, and the potential predictive factors for response and the impact of response on overall survival remain unclear.